$10B Amgen Bid Snubbed By Onyx Pharmaceuticals
The board of directors for Onyx Pharmaceuticals Inc., a cancer-drug maker, has rejected an approximately $10 billion takeover offer made by Amgen Inc. and is now actively shopping itself to other...To view the full article, register now.
Already a subscriber? Click here to view full article